{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:52:53Z","timestamp":1779202373047,"version":"3.51.4"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:sec id=\"ab-dbr250007-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The Target Vitiligo Area Scoring Index (Target-VASI) is the primary tool for evaluating localized vitiligo lesions; however, its uncalibrated estimation in clinical practice is limited by intrarater and interrater variability. While objective methods using tracing papers or imaging systems are available, these approaches are often tedious and rely on images that are not well contrasted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr250007-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the reliability and the performance of a semiautomatic analysis of the lesions performed on standardized UV reflectance pictures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr250007-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>\n                      This validation study was part of a prospective, double-blind, randomized, placebo-controlled clinical trial conducted between September 2023 and February 2024 at a tertiary care center to evaluate a grafting-based therapy in difficult-to-treat vitiligo lesions. Participants included adult patients with a pair of stable vitiligo target lesions with surface areas between 2 cm\n                      <jats:sup>2<\/jats:sup>\n                      and 20 cm\n                      <jats:sup>2<\/jats:sup>\n                      . Target-VASI was measured prior to treatment and 12 weeks after treatment by using 3 methods: the image-based system (UV image Target-VASI), tracing paper outlines (tracing paper Target-VASI), and assessments by an experienced clinician (clinician Target-VASI). The image-based system involved semiautomatic analysis of standardized UV reflectance images.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr250007-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The Target-VASI estimation methods were compared for correlation, agreement, and repeatability, with relationships scored as weak, moderate, good\/strong, and very good\/very strong based on results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr250007-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 20 adult patients with a pair of stable vitiligo target lesions of surface area between 2 cm\n                      <jats:sup>2<\/jats:sup>\n                      and 20 cm\n                      <jats:sup>2<\/jats:sup>\n                      were enrolled. One was lost to follow-up, resulting in 19 evaluable participants included for the analysis. The mean (SD) age was 51.7 (10.7) years, and 12 (63.8%) were female. The mean (SD) vitiligo duration was 21.2 (14.4) years. A total of 61 tracing paper Target-VASIs and 76 UV image and clinician Target-VASIs were available for analysis. UV image Target-VASIs demonstrated strong correlations with tracing paper (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.81 [95% CI, 0.71-0.89];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) and clinician (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.89 [95% CI, 0.83-0.93];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) Target-VASIs. The agreement was also good, with mean (SD) biases of 0.81 (0.99) and 0.52 (0.76) for tracing paper and clinician Target-VASIs, respectively. Additionally, an intraclass correlation coefficient of 0.79 (95% CI, 0.60-0.88) indicated moderate to good reproducibility of Target-VASI measurements. Although errors, such as nonmatching lesion regions and oversegmented pigmentation, were identified, the overall UV image Target-VASI accuracy was largely maintained due to the precise detection of depigmented areas.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr250007-9\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this investigation, the image-based system demonstrated reliable performance, suggesting its possible use in studies or routine clinical practice as a more efficient alternative to conventional approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.2740","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:00:35Z","timestamp":1758121235000},"page":"1157","source":"Crossref","is-referenced-by-count":2,"title":["Objective Assessment of Target Vitiligo Areas by Semiautomatic Analysis of Standardized UV Images"],"prefix":"10.1001","volume":"161","author":[{"given":"Charles","family":"Jabour","sequence":"first","affiliation":[{"name":"QuantifiCare, Biot, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Bletterer","sequence":"additional","affiliation":[{"name":"QuantifiCare, Biot, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e9 C\u00f4te d\u2019Azur, CHU Nice, Nice, France"},{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, INSERM, U1065, C3M, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"10","key":"dbr250007r1","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/jdv.18257","article-title":"Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA.","volume":"36","author":"Bibeau","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"dbr250007r2","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archderm.140.6.677","article-title":"Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index.","volume":"140","author":"Hamzavi","year":"2004","journal-title":"Arch Dermatol"},{"issue":"7","key":"dbr250007r3","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/jdv.16226","article-title":"Ultraviolet photography in vitiligo: image quality, validity and reliability.","volume":"34","author":"Uitentuis","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"dbr250007r4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jdin.2023.06.008","article-title":"Reliability of the Vitiligo Area Scoring Index measurement tool for vitiligo.","volume":"16","author":"Pourang","year":"2023","journal-title":"JAAD Int"},{"issue":"5","key":"dbr250007r5","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/bjd.17190","article-title":"Reference method for digital surface measurement of target lesions in vitiligo: a comparative analysis.","volume":"180","author":"van Geel","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"dbr250007r6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1755-148X.2007.00426.x","article-title":"An objective method for the assessment of vitiligo treatment.","volume":"21","author":"Marrakchi","year":"2008","journal-title":"Pigment Cell Melanoma Res"},{"key":"dbr250007r7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1200963","article-title":"Non-invasive skin measurement methods and diagnostics for vitiligo: a systematic review.","volume":"10","author":"Abdi","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"dbr250007r8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/bjd\/ljad304","article-title":"Reliability and agreement testing of a new automated measurement method to determine facial vitiligo extent using standardized ultraviolet images and a dedicated algorithm.","volume":"190","author":"Marin Dit Bertoud","year":"2023","journal-title":"Br J Dermatol"},{"key":"dbr250007r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2020.101743","article-title":"Ultraviolet imaging in dermatology.","volume":"30","author":"Mojeski","year":"2020","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"2","key":"dbr250007r12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/ics.12591","article-title":"UV reflectance photography of skin: what are you imaging?","volume":"42","author":"Crowther","year":"2020","journal-title":"Int J Cosmet Sci"},{"key":"dbr250007r13","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf143","article-title":"Promoting Repigmentation after Epidermal cell suspension grafting and preVENTing the loss of melanocytes using topical ruxolitinib for vitiligo in resistant areas (PREVENT): a prospective monocentric interventional double-blind study.","author":"Dugourd","year":"2025","journal-title":"Br J Dermatol"},{"issue":"2","key":"dbr250007r14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research.","volume":"15","author":"Koo","year":"2016","journal-title":"J Chiropr Med"},{"issue":"5","key":"dbr250007r15","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","article-title":"Correlation coefficients: appropriate use and interpretation.","volume":"126","author":"Schober","year":"2018","journal-title":"Anesth Analg"},{"key":"dbr250007r9","author":"Bian"},{"key":"dbr250007r10","author":"Low"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2838595\/jamadermatology_jabour_2025_br_250007_1762976626.14456.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T16:00:42Z","timestamp":1763568042000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2838595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.2740","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}